775. Deputy Ken O'Flynn asked the Minister for Health whether any review has been undertaken into the drivers of variation in average reimbursement cost per salbutamol nebule item under the General Medical Services scheme since 2024. [36450/26]
Parliamentary questions
Questions
TDs ask ministers questions to get answers on the record, most of them in writing. Here is every one asked in the 34th Dáil, by the department it went to and the subject heading it was filed under. How questions work
Browse the questions
Showing questions asked by Ken O'Flynn under the heading Medicinal Products.
196 questions match, newest first.
777. Deputy Ken O'Flynn asked the Minister for Health whether the Department has assessed the extent to which high-frequency salbutamol dispensing may indicate gaps in preventative asthma or COPD management in primary care. [36452/26]
778. Deputy Ken O'Flynn asked the Minister for Health whether the HSE has identified any supply-chain, pricing or reimbursement pressures affecting nebulised respiratory medications since 2024. [36453/26]
540. Deputy Ken O'Flynn asked the Minister for Health to clarify the current operational status of any early access or compassionate access schemes for rare disease medicines; and to confirm whether any such schemes are currently available to patients in Ireland. [33756/26]
942. Deputy Ken O'Flynn asked the Minister for Health whether national clinical guidelines are in place governing access to pharmacological treatments for obesity within the public health service; if so, to provide details of those guidelines and the eligibility criteria applied; and if she will make a statement on the matter. [32352/26]
944. Deputy Ken O'Flynn asked the Minister for Health whether any procurement or reimbursement decisions are under consideration in relation to new pharmacological treatments for obesity; if so, to outline the current status of those considerations and the decision-making framework applied; and if she will make a statement on the matter. [32354/26]
1121. Deputy Ken O'Flynn asked the Minister for Health whether any patients in the State currently have access to omaveloxolone, marketed as Skyclarys, for Friedreich’s ataxia through compassionate use, named patient access, hospital-level approval, exceptional funding, or any other interim access mechanism pending a final HSE reimbursement decision; and if she will make a statement on the matter. [32771/26]
1122. Deputy Ken O'Flynn asked the Minister for Health the number of patients in the State known to the HSE or the Department of Health who are clinically eligible for treatment with omaveloxolone, marketed as Skyclarys, for Friedreich’s ataxia; and if this number has informed any budget impact assessment. [32772/26]
1123. Deputy Ken O'Flynn asked the Minister for Health whether the HSE has a target timeline for completing reimbursement decisions in respect of orphan medicines or medicines for progressive rare diseases; and if no such target exists, whether one is under consideration. [32773/26]
1124. Deputy Ken O'Flynn asked the Minister for Health whether the HSE has any escalation process where a reimbursement application concerns a progressive neurological condition in which delay may lead to irreversible deterioration. [32774/26]
1125. Deputy Ken O'Flynn asked the Minister for Health whether the HSE has considered international reimbursement or access decisions in respect of omaveloxolone, marketed as Skyclarys, including decisions in France, Italy, Germany or other comparable European countries, as part of the Irish reimbursement process. [32775/26]
1126. Deputy Ken O'Flynn asked the Minister for Health whether the Department or HSE has examined the favourable reimbursement opinion issued in France for Skyclarys in Friedreich’s ataxia, and whether such international assessments are considered in Irish rare disease reimbursement decisions. [32776/26]
1127. Deputy Ken O'Flynn asked the Minister for Health whether the Department or HSE is aware that Italy’s medicines authority approved reimbursement of Skyclarys for Friedreich’s ataxia in December 2025, and whether this decision has been considered in the Irish process. [32777/26]
1128. Deputy Ken O'Flynn asked the Minister for Health whether the HSE has received a commercial proposal from Biogen Idec Ireland Limited in respect of omaveloxolone, marketed as Skyclarys, since 16 April 2026; and if not, what steps the HSE is taking to progress the matter. [32778/26]
1129. Deputy Ken O'Flynn asked the Minister for Health whether any statutory, contractual, policy or administrative time limits apply where a marketing authorisation holder has been invited to submit a commercial proposal for a medicine but has not yet done so. [32779/26]
1130. Deputy Ken O'Flynn asked the Minister for Health whether she will consider introducing a formal interim access pathway for rare disease medicines where a treatment has European marketing authorisation, there is no alternative disease-modifying therapy available, and the reimbursement process remains unresolved. [32780/26]
1157. Deputy Ken O'Flynn asked the Minister for Health whether her Department receives aggregated national reporting on waiting times for access to PrEP services; and if so, to provide the most recent data. [32892/26]
1158. Deputy Ken O'Flynn asked the Minister for Health whether a national register or centralised data system exists to track demand for PrEP services across all providers; and if not, whether one is planned. [32893/26]
1159. Deputy Ken O'Flynn asked the Minister for Health the total number of clinics currently delivering PrEP services nationally, including both public and private providers, and whether this number has increased since 2023. [32894/26]
1160. Deputy Ken O'Flynn asked the Minister for Health whether any national standard exists for maximum acceptable waiting times for access to PrEP services; and if not, whether such a standard will be introduced. [32895/26]
1161. Deputy Ken O'Flynn asked the Minister for Health whether her Department has assessed geographic disparities in access to PrEP services; and if so, to provide details of any identified gaps. [32896/26]
1162. Deputy Ken O'Flynn asked the Minister for Health the estimated number of individuals unable to access PrEP services due to capacity constraints in the most recent year. [32897/26]
1163. Deputy Ken O'Flynn asked the Minister for Health whether any interim or bridging access arrangements exist for individuals clinically eligible for PrEP but unable to secure an appointment within the public system. [32898/26]
1164. Deputy Ken O'Flynn asked the Minister for Health whether funding allocated to expand PrEP capacity in 2025 and 2026 has been fully utilised; and if not, the reasons for any underspend. [32899/26]
239. Deputy Ken O'Flynn asked the Minister for Health whether an application has been received for the reimbursement of the drug skyclarys for the treatment of Friedreich’s ataxia; if so, the current status of that application; the date on which it was submitted to the National Centre for Pharmacoeconomics; and the expected timeline for a final reimbursement decision. [29078/26]